Literature DB >> 27680976

miRNAs in non-alcoholic fatty liver disease.

Zhen He1, Cheng Hu2, Weiping Jia1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver cirrhosis and hepatocellular carcinoma and is a considerable threat to public health. miRNAs are important post-transcriptional regulators of gene expression, and the dysregulation of miRNAs is involved in various biological processes in the liver, including lipid homeostasis, inflammation, apoptosis, and cell proliferation. Recently, a number of studies have described the association between miRNAs and NAFLD progression and have shown that circulating miRNAs reflect histological changes in the liver. Therefore, circulating miRNAs have potential use for the evaluation of NAFLD severity. In this review, we discuss the involvement of miRNAs in NAFLD pathogenesis and the key role of miRNAs in the screening, diagnosis, and staging of NAFLD.

Entities:  

Keywords:  hepatocellular carcinoma; miRNA; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2016        PMID: 27680976     DOI: 10.1007/s11684-016-0468-5

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  56 in total

1.  Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.

Authors:  Ling Yang; Yoon Seok Roh; Jingyi Song; Bi Zhang; Cheng Liu; Rohit Loomba; Ekihiro Seki
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

2.  Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice.

Authors:  Igor P Pogribny; Athena Starlard-Davenport; Volodymyr P Tryndyak; Tao Han; Sharon A Ross; Ivan Rusyn; Frederick A Beland
Journal:  Lab Invest       Date:  2010-06-14       Impact factor: 5.662

3.  Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.

Authors:  Raymond Ng; Heng Wu; Hong Xiao; Xin Chen; Holger Willenbring; Clifford J Steer; Guisheng Song
Journal:  Hepatology       Date:  2014-05-19       Impact factor: 17.425

Review 4.  The role of microRNAs in cholesterol efflux and hepatic lipid metabolism.

Authors:  Kathryn J Moore; Katey J Rayner; Yajaira Suárez; Carlos Fernández-Hernando
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

5.  Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.

Authors:  Hiroya Yamada; Koji Suzuki; Naohiro Ichino; Yoshitaka Ando; Akira Sawada; Keisuke Osakabe; Keiko Sugimoto; Koji Ohashi; Ryouji Teradaira; Takashi Inoue; Nobuyuki Hamajima; Shuji Hashimoto
Journal:  Clin Chim Acta       Date:  2013-05-30       Impact factor: 3.786

6.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

7.  Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.

Authors:  Davide Povero; Akiko Eguchi; Hongying Li; Casey D Johnson; Bettina G Papouchado; Alexander Wree; Karen Messer; Ariel E Feldstein
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

8.  A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.

Authors:  Youwen Tan; Guohong Ge; Tengli Pan; Danfeng Wen; Jianhe Gan
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

9.  MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.

Authors:  Heng Wu; Raymond Ng; Xin Chen; Clifford J Steer; Guisheng Song
Journal:  Gut       Date:  2015-08-17       Impact factor: 23.059

10.  miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.

Authors:  Junjie Xiao; Yihua Bei; Jingqi Liu; Jasmina Dimitrova-Shumkovska; Dapeng Kuang; Qiulian Zhou; Jin Li; Yanning Yang; Yang Xiang; Fei Wang; Changqing Yang; Wenzhuo Yang
Journal:  J Cell Mol Med       Date:  2015-12-09       Impact factor: 5.310

View more
  8 in total

1.  Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity.

Authors:  Rai Ajit K Srivastava
Journal:  J Diabetes Metab Disord       Date:  2018-11-29

Review 2.  The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application.

Authors:  Yu Xiang; Li Mao; Mei-Ling Zuo; Gui-Lin Song; Li-Ming Tan; Zhong-Bao Yang
Journal:  Mediators Inflamm       Date:  2022-06-17       Impact factor: 4.529

3.  Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Authors:  Rebeca Escutia-Gutiérrez; J Samael Rodríguez-Sanabria; C Alejandra Monraz-Méndez; Jesús García-Bañuelos; Arturo Santos-García; Ana Sandoval-Rodríguez; Juan Armendáriz-Borunda
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

4.  Association between rs2303861 polymorphism in CD82 gene and non-alcoholic fatty liver disease: a preliminary case-control study.

Authors:  Parham Habibzadeh; Behnam Honarvar; Mohammad Silawi; Shima Bahramjahan; Azar Kazemi; Mohammad Ali Faghihi; Kamran Lankarani
Journal:  Croat Med J       Date:  2019-08-31       Impact factor: 1.351

5.  Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles.

Authors:  Maoxing Pan; Yuanjun Deng; Chuiyang Zheng; Huan Nie; Kairui Tang; Yupei Zhang; Qinhe Yang
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-14       Impact factor: 2.629

6.  Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study.

Authors:  Reda Albadawy; Sara H A Agwa; Eman Khairy; Maha Saad; Naglaa El Touchy; Mohamed Othman; Mohamed El Kassas; Marwa Matboli
Journal:  Genes (Basel)       Date:  2021-11-18       Impact factor: 4.096

7.  Portulaca oleracea L. Extract Regulates Hepatic Cholesterol Metabolism via the AMPK/MicroRNA-33/34a Pathway in Rats Fed a High-Cholesterol Diet.

Authors:  Sojeong Jang; Mak-Soon Lee; Sun-A Kang; Chong-Tai Kim; Yangha Kim
Journal:  Nutrients       Date:  2022-08-14       Impact factor: 6.706

8.  mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.

Authors:  Marwa Matboli; Shaimaa H Gadallah; Wafaa M Rashed; Amany Helmy Hasanin; Nada Essawy; Hala M Ghanem; Sanaa Eissa
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.